Drug development in neuropsychopharmacology

Area of Science:

• Neuropsychopharmacology
• Personalized Medicine
• Biomarker Discovery

Background:

• Personalized medicine approaches in neuropsychopharmacology drug development are in early stages.
• Clinical application requires robust biomarkers for predicting drug response, tolerability, and safety, which are currently lacking.
• The field of dementia research may offer the first significant clinical relevance for personalized medicine in this domain.

Purpose of the Study:

• To highlight the current limitations in personalized medicine for neuropsychopharmacology drug development.
• To identify the need for clinically relevant biomarkers.
• To suggest that dementias represent a potential early area for clinical application.

Main Methods:

• Review of current state of personalized medicine in neuropsychopharmacology.
• Identification of biomarker gaps for drug response and safety.
• Discussion of potential clinical translation in dementia.

Main Results:

• Personalized medicine in neuropsychopharmacology drug development is nascent.
• Clinically relevant biomarkers for drug response and safety are largely unidentified.
• Dementias are proposed as a potential early clinical application area.

Conclusions:

• Significant advancements in biomarker identification are needed for personalized neuropsychopharmacology.
• Genotyping of drug-metabolizing enzymes requires validation through rigorous clinical trials.
• Personalized medicine holds promise for future neuropsychopharmacological treatments, particularly in dementia care.